Latest News and Press Releases

GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product...

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1...

The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD)...

Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000...

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease...

Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...

OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results